HK1063314A1 - Isoindolin-1-one glucokinase activators - Google Patents

Isoindolin-1-one glucokinase activators

Info

Publication number
HK1063314A1
HK1063314A1 HK04106031A HK04106031A HK1063314A1 HK 1063314 A1 HK1063314 A1 HK 1063314A1 HK 04106031 A HK04106031 A HK 04106031A HK 04106031 A HK04106031 A HK 04106031A HK 1063314 A1 HK1063314 A1 HK 1063314A1
Authority
HK
Hong Kong
Prior art keywords
isoindolin
glucokinase activators
glucokinase
activators
diabetes
Prior art date
Application number
HK04106031A
Other languages
English (en)
Inventor
Kevin Richard Guertin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1063314A1 publication Critical patent/HK1063314A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
HK04106031A 2000-12-13 2004-08-11 Isoindolin-1-one glucokinase activators HK1063314A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25527300P 2000-12-13 2000-12-13
US31871501P 2001-09-13 2001-09-13
PCT/EP2001/014404 WO2002048106A2 (en) 2000-12-13 2001-12-07 Isoindolin-1-one glucokinase activators

Publications (1)

Publication Number Publication Date
HK1063314A1 true HK1063314A1 (en) 2004-12-24

Family

ID=26944583

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04106031A HK1063314A1 (en) 2000-12-13 2004-08-11 Isoindolin-1-one glucokinase activators

Country Status (36)

Country Link
US (1) US6482951B2 (xx)
EP (1) EP1349856B1 (xx)
JP (1) JP4021766B2 (xx)
KR (1) KR100520651B1 (xx)
CN (1) CN1247574C (xx)
AT (1) ATE297922T1 (xx)
AU (2) AU2002238415B2 (xx)
BG (1) BG107903A (xx)
BR (1) BR0116169A (xx)
CA (1) CA2430579C (xx)
CY (1) CY1105587T1 (xx)
CZ (1) CZ20031882A3 (xx)
DE (1) DE60111570T2 (xx)
DK (1) DK1349856T3 (xx)
EG (1) EG24358A (xx)
ES (1) ES2243578T3 (xx)
HK (1) HK1063314A1 (xx)
HR (1) HRP20030450B1 (xx)
HU (1) HUP0400587A3 (xx)
IL (2) IL156264A0 (xx)
MA (1) MA26973A1 (xx)
MX (1) MXPA03005170A (xx)
MY (1) MY136741A (xx)
NO (1) NO325810B1 (xx)
NZ (1) NZ526236A (xx)
PA (1) PA8534601A1 (xx)
PE (1) PE20020593A1 (xx)
PL (1) PL366006A1 (xx)
PT (1) PT1349856E (xx)
RS (1) RS50933B (xx)
RU (1) RU2249590C2 (xx)
SI (1) SI1349856T1 (xx)
SK (1) SK8732003A3 (xx)
TW (1) TWI294876B (xx)
UY (1) UY27069A1 (xx)
WO (1) WO2002048106A2 (xx)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
MXPA05003391A (es) 2002-10-03 2005-06-22 Hoffmann La Roche Indol-3-carboxamidas como activadores de glucocinasa.
BR0314864A (pt) 2002-10-03 2005-08-02 Novartis Ag Compostos orgânicos
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
AU2003294376A1 (en) * 2003-01-06 2004-08-10 Eli Lilly And Company Heteroaryl compounds
WO2004072066A1 (en) * 2003-02-11 2004-08-26 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
CA2560689C (en) 2004-04-02 2011-03-01 Novartis Ag Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful in the treatment of type 2 diabetes
AU2005229415B2 (en) * 2004-04-02 2009-05-14 Novartis Ag Thiazolopyridine derivatives, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
US20090281142A1 (en) * 2005-08-31 2009-11-12 Astellas Pharma Inc. Thiazole derivative
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
BRPI0617207A2 (pt) 2005-09-29 2011-07-19 Sanofi Aventis derivados de fenil-1,2,4-oxadiazolona, processos para sua preparação e seu uso como produtos farmacêuticos
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
WO2007053662A1 (en) 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Dihydroisoindolones as allosteric modulators of glucokinase
EP1951707A1 (en) * 2005-11-01 2008-08-06 Janssen Pharmaceutica N.V. Substituted pyrrolones as allosteric modulators of glucokinase
JP2009513720A (ja) * 2005-11-01 2009-04-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ グルコキナーゼのアロステリックモジュレーターとしての置換シクロアルキルピロロン
JP2009513704A (ja) * 2005-11-01 2009-04-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ グルコキナーゼのアロステリックモジュレーターとしての置換ジヒドロイソインドロン
JP2009514835A (ja) * 2005-11-03 2009-04-09 プロシディオン・リミテッド トリシクロ置換型アミド
EP1948614A2 (en) * 2005-11-18 2008-07-30 Takeda San Diego, Inc. Glucokinase activators
JP5302012B2 (ja) * 2006-03-08 2013-10-02 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP2049518B1 (en) 2006-05-31 2011-08-31 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents.
WO2008074694A1 (en) * 2006-12-20 2008-06-26 F. Hoffmann-La Roche Ag Crystallization of glucokinase activators
EP2091947A2 (en) 2006-12-20 2009-08-26 Takeda San Diego, Inc. Glucokinase activators
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
TW200902489A (en) 2007-03-07 2009-01-16 Kyorin Seiyaku Kk Glucokinase-activating substance
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
AR070107A1 (es) * 2008-01-15 2010-03-17 Lilly Co Eli R-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida en forma cristalina, composicion farmaceutica que la comprende y su uso para la manufactura de un medicamento util para la prevencion o tratamiento de hiperglicemia
AU2008348817B2 (en) * 2008-01-24 2011-12-15 Merck Patent Gmbh Beta-amino acid derivatives for treatment of diabetes
EP2275414B1 (en) * 2008-04-28 2015-06-10 Kyorin Pharmaceutical Co., Ltd. Cyclopentylacrylamide derivative
GEP20135783B (en) 2008-05-16 2013-03-11 Takeda California Inc Glucokinase activators
CA2735184C (en) * 2008-09-11 2013-05-28 Pfizer Inc. Heteroaryls amide derivatives and their use as glucokinase activators
CN105176930B (zh) 2010-03-31 2021-05-04 斯克里普斯研究所 重编程细胞
US8178689B2 (en) * 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AU2012223337C1 (en) 2011-03-01 2016-11-10 Bausch Health Ireland Limited Process of preparing guanylate cyclase C agonists
US8470866B2 (en) * 2011-05-03 2013-06-25 Hoffmann-La Roche Inc. Isoindolinone derivatives
LT3004076T (lt) * 2013-05-27 2020-01-10 F. Hoffmann-La Roche Ag Nauji 3,4-dihidro-2h-izochinolin-1-ono ir 2,3-dihidro-izoindol-1-ono junginiai
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
AU2015308350B2 (en) 2014-08-29 2020-03-05 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
CN109952292A (zh) 2016-10-14 2019-06-28 Tes制药有限责任公司 α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂
AR117122A1 (es) 2018-11-20 2021-07-14 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687147A1 (fr) * 1992-02-11 1993-08-13 Union Pharma Scient Appl Nouveaux derives d'alpha-amino n-pyridyl benzene propanamide, leurs procedes de preparation, compositions pharmaceutiques les contenant.
MXPA01009814A (es) 1999-03-29 2002-04-24 Hoffmann La Roche Activadores de la glucoquinasa.
DE60113247T2 (de) 2000-05-03 2006-06-22 F. Hoffmann-La Roche Ag Hydantoin-enthaltende glucokinase aktivatoren
DE60106599T2 (de) 2000-05-08 2006-02-09 F. Hoffmann-La Roche Ag Substituierte phenylacetamide und ihre verwendung als glukokinase aktivatoren

Also Published As

Publication number Publication date
JP4021766B2 (ja) 2007-12-12
TWI294876B (en) 2008-03-21
RS50933B (sr) 2010-08-31
MA26973A1 (fr) 2004-12-20
CA2430579A1 (en) 2002-06-20
UY27069A1 (es) 2002-07-31
CN1481382A (zh) 2004-03-10
HRP20030450B1 (en) 2006-02-28
HUP0400587A3 (en) 2011-03-28
CZ20031882A3 (cs) 2003-12-17
PE20020593A1 (es) 2002-07-06
CN1247574C (zh) 2006-03-29
ES2243578T3 (es) 2005-12-01
RU2249590C2 (ru) 2005-04-10
NO20032674L (no) 2003-06-12
AU2002238415B2 (en) 2007-01-04
JP2004521095A (ja) 2004-07-15
EG24358A (en) 2009-03-04
EP1349856A2 (en) 2003-10-08
MY136741A (en) 2008-11-28
WO2002048106A2 (en) 2002-06-20
ATE297922T1 (de) 2005-07-15
WO2002048106A3 (en) 2002-11-28
YU47703A (xx) 2006-05-25
PL366006A1 (en) 2005-01-24
DE60111570T2 (de) 2006-05-11
MXPA03005170A (es) 2003-09-22
US20020082260A1 (en) 2002-06-27
DK1349856T3 (da) 2005-10-17
CY1105587T1 (el) 2010-07-28
HRP20030450A2 (en) 2005-04-30
PT1349856E (pt) 2005-09-30
NZ526236A (en) 2004-12-24
US6482951B2 (en) 2002-11-19
PA8534601A1 (es) 2002-08-26
BG107903A (bg) 2004-02-27
SI1349856T1 (en) 2005-10-31
IL156264A0 (en) 2004-01-04
NO325810B1 (no) 2008-07-21
KR100520651B1 (ko) 2005-10-11
DE60111570D1 (de) 2005-07-21
BR0116169A (pt) 2003-12-23
CA2430579C (en) 2010-01-26
SK8732003A3 (en) 2004-04-06
EP1349856B1 (en) 2005-06-15
IL156264A (en) 2010-11-30
NO20032674D0 (no) 2003-06-12
HUP0400587A2 (hu) 2004-06-28
AU3841502A (en) 2002-06-24
KR20030064817A (ko) 2003-08-02

Similar Documents

Publication Publication Date Title
EG24358A (en) Isoindolin-1-one glucokinase avtivators
MY180762A (en) Combination therapy comprising glucose reabsorption inhibitors and ppar modulators.
MY135222A (en) Substituted phenylacetamides and their use as glucokinase activators
MY136764A (en) Indole-3-carboxamides as glucokinase (gk) activators
MXPA05008406A (es) Compuestos de amida tri(ciclo)-sustituida.
MY136926A (en) Glucokinase activators
WO2001083465A3 (en) Alkynyl phenyl heteroaromatic glucokinase activators
PT1311504E (pt) Tetrazolil-fenil-acetamidas activadoras da glucoquinase
YU68002A (sh) Modifikovani faktor viii
JO2180B1 (en) Glucokinase Trans olivine steroids
IL144948A0 (en) Electroactive pore
PT1282611E (pt) Fenilacetamidas substituidas e sua utilizacao como activadores da glucocinase
UA84025C2 (xx) СПОЛУКИ 2-(ХІНОКСАЛІН-5-ІЛСУЛЬФОНІЛАМІНО)-БЕНЗАМІДУ ЯК МОДУЛЯТОРИ ССК2$Normal;heading 1;heading 2;СОЕДИНЕНИЯ 2-(ХИНОКСАЛИН-5-ИЛСУЛЬФОНИЛАМИНО)-БЕНЗАМИДА КАК МОДУЛЯТОРЫ ССК2
MXPA02008722A (es) Inhibidores novedosos de aril fructosa-1,6-bisfosfatasa.
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
PT1435991E (pt) Utilização de aplidina para o tratamento de cancro pancreático
RS20050733A (xx) Jedinjenja benzo /1,2,5/tiadiazola
WO2002024181A3 (en) The use of melatonin for induction of general anesthesia
JO2238B1 (en) Glycine stimulants iswindline 1- on
EP1251847A4 (en) NEW USE OF PRODIGIOSIN FOR THE TREATMENT OF DIABETES MELLITUS
UA70017A (en) Method for conservative treatment of chronic tonsillitis in adults
MXPA04003673A (es) Uso de aplidina para el tratamiento de cancer pancreatico.
UA32466C2 (uk) Комплексний інфузійний препарат "реосорбілакт"
MD1919F2 (en) Medicinal remedy
ZA200107918B (en) The treatment of rubber.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20101207